3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
Specimen Handling
631
pembrolizumab
610
Magnetic Resonance Spectroscopy
553
Carboplatin
450
Cisplatin
398
Cyclophosphamide
397
Biopsy
375
Nivolumab
326
Paclitaxel
324
Gemcitabine
317
Radiotherapy
286
Bevacizumab
244
Dexamethasone
222
fludarabine
215
Docetaxel
199
durvalumab
195
venetoclax
188
Oxaliplatin
187
atezolizumab
184
Fluorouracil
177
Rituximab
176
Pemetrexed
173
Capecitabine
169
Radiation
167
Doxorubicin
166
Radiosurgery
159
Ipilimumab
147
Etoposide
142
Leucovorin
141
Lenalidomide
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
SGN-LIV1A
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled